Thursday, July 16, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSEJohnson's $95 Billion Defense Spending Plan Has Lockheed, RTX, and Northrop Written All Over IttodayDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat4 weeks agoTRADE & TARIFFSPepsiCo's Tariff Refund Is a Small Win, But It Points to a Broader Cost Relief Story for Consumer StaplestodayENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom4 weeks agoENERGYTrump's Nuclear Push Is Driving a Real Uranium Mining Revival — These Are the Stocks That CollecttodayDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch4 weeks agoWHITE HOUSETrump Shrinks Two Utah Monuments by 90%, Opening Land to Mining and DrillingtodayDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes4 weeks agoHEALTHCARE & FDACMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM RivalstodayDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization4 weeks agoWHITE HOUSEWhite House 'Gold Eagle' AI Cyber Clearinghouse Is a Slow-Burn Contract Opportunity for Cybersecurity FirmstodayENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear4 weeks agoDEFENSEPentagon's Laser Weapon Contracts for Drone Defense Hand a Direct Win to Directed-Energy SpecialiststodayENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch4 weeks agoENERGYPalisades Restart and Trump's Nuclear Push Are Turning Uranium Miners Into a Policy TradeyesterdayDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop4 weeks agoHEALTHCARE & FDAHHS Fraud Crackdown on Medicare Advantage Puts Managed Care Insurers and For-Profit Hospitals on DefenseyesterdayENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade4 weeks agoDEFENSEThe UK's £300 Billion Defense Plan Is a Revenue Opportunity for U.S. Contractors — If They Can Win the BidsyesterdayDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One4 weeks agoWHITE HOUSEESA 'Harm' Definition Rescinded — Extractive Industries Get Regulatory Relief, Conservation Stocks Face Uncertainty2 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money4 weeks agoENERGYPalisades Nuclear Restart and New SMR Plans Put Holtec — and Its Public Suppliers — in the Spotlight2 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors4 weeks agoDEFENSENATO Members Racing to 3.5% GDP Defense Spending — U.S. Contractors Are the Biggest Beneficiaries2 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus4 weeks agoCRYPTOThe CLARITY Act Could Redraw Crypto's Regulatory Map — Here's Which Public Names Win2 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI4 weeks agoMARKETSDOJ Kills TransDigm's $960M Deal — The Acquirer Takes the Hit, the Target Gets a Second Life2 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive4 weeks agoTRADE & TARIFFSBIS Lifts Export Restrictions on UAE — Chip and Defense Tech Sellers Get a New Customer2 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime4 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Winners — and They're Already Public2 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending4 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Stock Winners — and a Cryptography Deadline That Hurts Laggards3 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for Lockheed, RTX, and Northrop3 days agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market3 days agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics3 weeks agoCRYPTOVanguard's Crypto Pivot Signals Institutional Capitulation — Coinbase and Robinhood Are the Infrastructure Winners3 days agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction3 weeks agoWHITE HOUSETrump's Subpoenas of NYT Reporters Create Legal Overhang for News Publishers — and a Tailwind for First Amendment Litigators3 days agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet3 weeks agoENERGYFederal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the Month3 days agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos3 weeks agoWHITE HOUSEFTC Forces Deere to Open Its Repair Tools — and Hands Independent Shops a Business Model3 days agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys3 weeks agoHEALTHCARE & FDAMedicare Advantage Plans Are Set to Collect $13 Billion in Quality Bonuses — UnitedHealth and Humana Lead the Queue3 days agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise3 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMD3 days agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Biggest Cost for SMR Developers3 days agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift3 weeks agoENERGYCommonwealth LNG Permit Moves Forward — Cheniere and ConocoPhillips Are Watching Closely4 days agoENERGYThe BLM Calendar That Moves COP and OXY3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Market4 days agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through3 weeks agoENERGYUSDA's Revamped Biorefinery Loan Guarantee Program Is a Quiet Tailwind for ADM and Renewable Chemical Producers4 days agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot3 weeks agoHEALTHCARE & FDATrump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed Signal4 days agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly3 weeks agoCRYPTOThe SEC's 2026 Crypto Regulatory Agenda Is a Green Light for Coinbase and Robinhood4 days agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently3 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Tools — Farmers Win, Deere's Software Moat Takes a Hit4 days agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil3 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMD4 days agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Clock for SMR Developers4 days agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes3 weeks agoDEFENSENATO's Spending Surge Is Real and Getting Enforced — RTX, Lockheed, and AeroVironment Are the Direct Beneficiaries4 days agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program3 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply Chain5 days agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order3 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers5 days agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine3 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct Beneficiaries5 days agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense Primes5 days agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR Timeline5 days agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream2 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry Wins5 days agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation2 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be Priced5 days agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX2 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone Away5 days agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet2 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sector6 days agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade2 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lilly6 days agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk2 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole Position6 days agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market6 days agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending2 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBM6 days agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political2 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in Years6 days agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers2 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and Northrop6 days agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch2 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiarieslast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock2 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winnerslast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Forever2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Playslast weekDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paid2 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Tradelast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market2 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel Itlast weekDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boom2 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Callslast weekTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Money2 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Moving2 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paidlast weekWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwind2 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhoodlast weekMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Tech2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeuticslast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Nameslast weekDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expenselast weekDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Tradelast weekCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risklast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironmentlast weekWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stacklast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironmentlast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivalslast weekTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiarieslast weekDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spotlast weekENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Tradelast weekTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immunelast weekHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Supplierslast weekHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payerlast weekTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Storylast weekHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiarylast weekCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling Itlast weekTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Meanslast weekENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stockslast weekENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Winlast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

CMS's Proposed 340B Payment Cuts Would Squeeze Hospital Revenue While Helping PBM Rivals

A federal proposal to cut what Medicare pays hospitals under the 340B drug discount program hits hospital systems hardest — and the FTC's Caremark settlement adds pressure on the other side.

Image: Money Racket
By at Money Racket·Jul 16, 2026

The Centers for Medicare & Medicaid Services has proposed cuts to 340B drug payment rates as part of a broader effort to lower Medicare costs, while HRSA separately reported that 340B program sales hit $100 billion in calendar year 2025. The 340B program allows safety-net hospitals to buy drugs at steep discounts and bill Medicare at higher rates — a spread that has become a major revenue line for large hospital systems.

Who cashes in: Specialty pharmacy operators and PBMs that compete with hospital outpatient pharmacies stand to gain if hospital 340B economics weaken and patient volume shifts. CVS Health CVS — which just settled an FTC antitrust case over its Caremark PBM — and Cigna's Express Scripts (CI) benefit if hospitals lose pricing advantage in outpatient drug dispensing. Smaller independent pharmacies, which the FTC settlement explicitly aims to help, could see volume gains, but there are no clean pure-play public tickers there.

Hospitals built entire revenue lines around the 340B spread. CMS is proposing to shrink that spread — and the hospital stocks most dependent on it have the least room to absorb the hit.

Who's exposed: Large nonprofit and for-profit hospital systems that have built revenue models around 340B spreads face the most direct hit. HCA Healthcare HCA, Tenet Healthcare THC, and Universal Health Services UHS all operate significant outpatient pharmacy and infusion operations where 340B revenue is material. Community Health Systems CYH, which operates in lower-income markets where 340B eligibility is concentrated, is particularly exposed. The cuts are proposed, not final — but the direction of travel is clear and has been for two years.

Watch the final CMS rule, expected later this year. If the cuts survive the comment period without significant rollback, hospital stocks with high 340B exposure will reprice. HCA and Tenet have enough scale to absorb it; CYH has less cushion.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →